$Amphastar Pharmaceuticals (AMPH.US)$Revenue has continued t...
$Amphastar Pharmaceuticals(AMPH.US$Revenue has continued to grow over the past 5 years, 14% in 2022, operating profit rapidly increased to 110 million after losing money in 2020, 53.8% in 2022, and net profit increased by 44.4% to 91 million in 2022.
2023Q1 revenue increased by 16.3%, operating profit increased 54.7%, and net profit increased 7.3%, mainly due to other net income of 9.07 million in the same period last year.
The balance ratio has not changed much in the past five years; it has basically fluctuated around 30%. The ratio and growth rate of accounts receivable and inventory are relatively normal.
Long-term loans of 73 million yuan, net assets of 550 million yuan, very low leverage ratio, and 198 million treasury stocks.
In the past three years, net cash flow from operations has begun to significantly exceed net investment, generating shareholder surpluses.
Currently, the price-earnings ratio is 25.4, the price-earnings ratio TTM24.9, and there is a certain discount compared to the growth rate, but high growth is inherently unsustainable, so you can choose carefully (⭐️)
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
